التفاصيل البيبلوغرافية
| العنوان: |
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy. |
| المؤلفون: |
Chan, Wei Yee, Sanchez, Emilie, Chavda, Selina J., Lecat, Catherine S. Y., Ainley, Louise, Xu, Ke, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Kyriakou, Charalampia, Sive, Jonathan, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Lee, Lydia, Nastouli, Eleni, Yong, Kwee L. |
| المصدر: |
British Journal of Haematology; Sep2021, Vol. 194 Issue 5, p857-861, 5p |
| مصطلحات موضوعية: |
PLASMA cell diseases, SARS-CoV-2, ANTIBODY formation, INFECTION, COVID-19, MULTIPLE myeloma |
| مستخلص: |
Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy Keywords: antibody response; COVID-19 disease; multiple myeloma; plasma cell disorders; SARS-CoV-2 EN antibody response COVID-19 disease multiple myeloma plasma cell disorders SARS-CoV-2 857 861 5 09/02/21 20210901 NES 210901 Patients with multiple myeloma and related plasma cell disorders (PCD) are considered extremely vulnerable to SARS-CoV-2 infection due to disease-related impaired humoral and cellular immunity as well as receipt of immunosuppressive therapy.1 Overall mortality from COVID-19 disease in 650 PCD patients across 10 countries was 33%.2 Poor outcomes from COVID-19 disease have resulted in recommendations for modifications to systemic anti-cancer therapy (SACT) to reduce the risk of infection whilst balancing the potential complications of untreated PCD.3 With the rollout of the COVID-19 vaccines, there is urgent need to understand seroconversion in immunocompromised patients for ongoing patient management and recommendation. Positive antibody test post PCR-confirmed infection occurred at a median of 86-5 days compared to 30-5 days for those who tested negative, suggesting a delayed response compared to the general population of 14-28 days.12 Our study and analyses are limited by small number of seropositive patients and those undergoing antibody testing post PCR-diagnosed COVID-19 disease. Patients with positive SARS-CoV-2 antibody test categorised by PCR-positive patients and unexpected antibody test positive patients. [Extracted from the article] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
